Citius Oncology Secures $36.5M Financing as LYMPHIR Launch Gains Traction
Event summary
- Citius Oncology generated $5.6M in net revenue in the first half of fiscal 2026, with 80% gross margins, from its LYMPHIR launch.
- The company secured up to $36.5M in debt and equity financing post-quarter-end, including a $10M term loan from Avenue Capital Group.
- 83% of target accounts have added LYMPHIR to formulary or are in review, with near 100% payer coverage and no reimbursement denials.
- Initial European shipments of LYMPHIR began in April 2026 under Named Patient Programs across 19 markets.
- Positive topline results from two investigator-initiated Phase 1 studies reinforce LYMPHIR's potential in combination settings.
The big picture
Citius Oncology's strategic focus on establishing LYMPHIR's position in the CTCL treatment journey is reinforced by strong formulary and payer access, healthy margins, and secured financing. The company's efforts to expand internationally and explore combination therapy potential align with broader industry trends toward targeted oncology treatments and global market access. With up to $36.5M in financing secured, Citius Oncology aims to drive continued momentum in a growing and underserved market estimated to exceed $400M.
What we're watching
- Commercial Scaling
- How Citius Oncology will deploy its full commercial team by mid-summer and sustain momentum with broad market access and sufficient inventory.
- International Expansion
- The pace at which Citius Oncology can expand LYMPHIR's availability beyond the U.S. through Named Patient Programs and secure new bulk drug substance suppliers.
- Combination Therapy Potential
- Whether LYMPHIR can establish itself as a platform asset in combination regimens, supported by ongoing clinical evidence generation.
Related topics